Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
GLP-1 receptor agonists mimic gut hormones to curb appetite and slow digestion, a mechanism driving the success of therapies from Novo Nordisk (Ozempic for diabetes and Wegovy for Lillys oral GLP-1 drug orforglipron achieves 12.4% weight loss in phase 3 trial but trails injectable rivals tirzepatide and retatrutide Lilly recently reported topline results from the ATTAIN-1 phase-3 trial evaluating orforglipron, a once-daily oral glucagon-like-peptide-1 (GLP-1) receptor agonist for adults with obesity or overweight without diabetes
[PMID: 12516429] PubMed record related to this compound for laboratory literature review
The evidence for divided dosing over single daily dosing is not established in humans
Food and Drug Administration published guidelines to assess the cardiovascular risk of novel antidiabetic drugs [27]
The demand for collagen masks and eye wrinkle treatments reflects a focus on anti-ageing and hydration, with targeted solutions for maintaining a youthful appearance
The cost barrier is equally structural: at USD 1,000-1,300 per month without insurance, GLP-1 drugs are affordable only to a small fraction of the global population who could benefit clinically, concentrating commercial market growth in the wealthy minority of the total addressable patient population
